

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(180) CA 125					52							52	50	96%
Samples and groups	[kU/L]													
Sample A		115	18	16	52							52	52	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		134	11	7,9	20	0	CVPG	135	1,7	20%	108	162	20	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		100	8,7	8,6	9	0	CVPG	103	2,2	20%	82,4	124	9	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		105	5,7	5,4	14	0	CVPG	102	0,84	20%	81,6	123	14	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		100	1,6	1,6	5	0	CVPG	101	1,8	20%	80,8	122	5	
Other					4	0							4	
														3x 4/29, 1x 4/149
Sample B		13,9	2,7	19	52							52	50	96%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		16,0	1,0	6,4	20	0	CVPG	16,2	0,29	20%	12,9	19,5	20	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		10,5	0,74	7,1	9	0	CVPG	10,5	0,38	20%	8,4	12,6	9	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		14,6	0,98	6,7	14	0	CVPG	14,3	0,14	20%	11,4	17,2	14	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		12,4	1,1	9,0	5	0	CVPG	12,2	0,36	20%	9,76	14,7	5	
Other					4	0							4	
														3x 4/29, 1x 4/149
(181) CA 15-3					47							47	46	98%
Samples and groups	[kU/L]													
Sample A		19,7	3,5	18	47							47	46	98%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		19,4	0,91	4,7	13	0	CVPG	19,4	0,29	18%	15,9	22,9	13	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		14,9	1,0	6,9	11	0	CVPG	14,7	0,36	18%	12	17,4	11	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		21,8	1,1	5,0	13	0	CVPG	21,6	0,20	18%	17,7	25,5	13	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		21,4	0,22	1,0	5	0	CVPG	20,3	0,33	18%	16,6	24	5	
Other					5	0							5	
														4x 4/29, 1x 4/149
Sample B		31,2	7,2	23	47							47	46	98%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		33,6	1,6	4,9	13	0	CVPG	34	0,65	18%	27,8	40,2	13	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		16,9	1,3	8,0	11	0	CVPG	16,3	0,54	18%	13,3	19,3	11	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		34,8	1,6	4,6	13	0	CVPG	34,5	0,33	18%	28,2	40,8	13	
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		35,0	1,4	4,0	5	0	CVPG	33,2	0,52	18%	27,2	39,2	5	
Other					5	0							5	
														4x 4/29, 1x 4/149
(182) CA 19-9					51							51	50	98%
Samples and groups	[kU/L]													
Sample A		6,39	2,1	33	51							51	50	98%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		4,62	0,46	10	15	0	CVPG	4,6	0,16	±2,8	1,8	7,4	15	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		5,39	0,44	8,2	11	0	CVPG	5,59	0,17	±2,8	2,79	8,39	11	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,27	0,54	6,5	16	0	CVPG	8,21	0,086	±2,89	5,41	11,1	16	
Other					9	0							9	
														4x 4/29, 1x 4/149, 4x 4/179
Sample B		147	150	100	51							51	51	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		351	35	10	15	0	CVPG	352	8,8	20%	281	423	15	
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		69,3	6,4	9,2	11	0	CVPG	65,8	1,9	20%	52,6	79	11	
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		45,7	1,8	3,9	16	0	CVPG	45,6	0,37	20%	36,4	54,8	16	
Other					9	0							9	
														4x 4/29, 1x 4/149, 4x 4/179
(183) CA 72-4					32							31	30	97%
Samples and groups	[kU/L]													
Sample A		9,95	0,72	7,2	32							31	30	97%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		9,91	0,67	6,8	31	0	CVPG	10,1	0,19	20%	8,08	12,2	31	
Other					1	0							0	
														1x 1/164
Sample B		3,04	0,18	6,0	32							31	31	100%

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(183) CA 72-4					32								31	30	97%
Samples and groups		[kU/L]													
Sample B		3,04	0,18	6,0	32								31	31	100%
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	3,03	0,17	5,6	31	0	CVPG	3,01	0,033	20%	2,4	3,62	31		
Other					1	0							0		
		1x 1/164													
(184) CYFRA 21-1					23								23	20	87%
Samples and groups		[µg/L]													
Sample A		19,7	1,2	6,2	23								23	23	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	20,1	1,1	5,7	6	0	CVPG	19,4	0,59	18%	15,9	22,9	6		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	19,5	1,3	6,6	17	0	CVPG	19	0,24	18%	15,5	22,5	17		
Sample B		3,57	0,47	13	23								23	20	87%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	3,23	0,26	8,0	6	0	CVPG	3,13	0,16	18%	2,56	3,7	6		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	3,69	0,44	12	17	0	CVPG	3,47	0,10	18%	2,84	4,1	17		
(185) AFP					52								51	50	98%
Samples and groups		[µg/L]													
Sample A		7,33	0,57	7,8	52								51	51	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	7,21	0,38	5,3	14	0	CVPG	7,27	0,088	20%	5,81	8,73	14		
(4) LIA (CLIA, CMIA, ECLIA); (12)	Beckman Coulter	6,92	0,51	7,3	10	0	CVPG	7,04	0,22	20%	5,63	8,45	10		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	7,72	0,42	5,5	13	0	CVPG	7,5	0,084	20%	6	9	13		
(4) LIA (CLIA, CMIA, ECLIA); (179)	Siemens (Bayer)	7,38	0,72	9,7	7	0	CVPG	7,56	0,28	20%	6,04	9,08	7		
Other					8	0							7		
		1x 1/36, 1x 3/24, 1x 3/25, 4x 4/29, 1x 4/149													
Sample B		67,9	6,8	10	52								51	50	98%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	66,7	3,0	4,4	14	0	CVPG	66,7	1,0	20%	53,3	80,1	14		
(4) LIA (CLIA, CMIA, ECLIA); (12)	Beckman Coulter	62,1	5,8	9,4	10	0	CVPG	61,6	2,5	20%	49,2	74	10		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	75,2	3,4	4,5	13	0	CVPG	73,4	0,91	20%	58,7	88,1	13		
(4) LIA (CLIA, CMIA, ECLIA); (179)	Siemens (Bayer)	67,7	1,9	2,7	7	0	CVPG	64,6	1,6	20%	51,6	77,6	7		
Other					8	0							7		
		1x 1/36, 1x 3/24, 1x 3/25, 4x 4/29, 1x 4/149													
(186) hCG					65								65	64	98%
Samples and groups		[U/L]													
Sample A		16,8	1,7	10	65								65	64	98%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	15,5	1,3	8,5	17	0	CVPG	15,4	0,31	18%	12,6	18,2	17		
(4) LIA (CLIA, CMIA, ECLIA); (12)	Beckman Coulter	18,2	1,2	6,4	12	0	CVPG	18,7	0,26	18%	15,3	22,1	12		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	16,4	1,1	6,9	16	0	CVPG	16,4	0,11	18%	13,4	19,4	16		
(4) LIA (CLIA, CMIA, ECLIA); (179)	Siemens (Bayer)	16,8	0,30	1,8	9	0	CVPG	17	0,27	18%	13,9	20,1	9		
(4) LIA (CLIA, CMIA, ECLIA); (210)	Roche HCG STAT	16,5	1,7	10	5	0	CVPG	16,2	1,6	18%	13,2	19,2	5		
Other					6	0							6		
		1x 3/25, 4x 4/29, 1x 4/149													
Sample B		269	48	18	65								65	65	100%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	229	12	5,1	17	0	CVPG	229	3,4	18%	187	271	17		
(4) LIA (CLIA, CMIA, ECLIA); (12)	Beckman Coulter	256	22	8,6	12	0	CVPG	255	5,6	18%	209	301	12		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	319	22	6,9	16	0	CVPG	313	3,3	18%	256	370	16		
(4) LIA (CLIA, CMIA, ECLIA); (179)	Siemens (Bayer)	245	3,9	1,6	9	0	CVPG	238	6,5	18%	195	281	9		
(4) LIA (CLIA, CMIA, ECLIA); (210)	Roche HCG STAT	275	27	9,9	5	0	CVPG	275	33	18%	225	325	5		
Other					6	0							6		
		1x 3/25, 4x 4/29, 1x 4/149													
(189) CEA					55								54	49	91%
Samples and groups		[µg/L]													
Sample A		2,02	0,29	14	55								54	50	93%
(4) LIA (CLIA, CMIA, ECLIA); (1)	Abbott	2,30	0,16	6,9	17	0	CVPG	2,27	0,036	16%	1,9	2,64	17		
(4) LIA (CLIA, CMIA, ECLIA); (12)	Beckman Coulter	1,89	0,18	9,3	12	0	CVPG	1,99	0,042	16%	1,67	2,31	12		
(4) LIA (CLIA, CMIA, ECLIA); (60)	Roche	1,96	0,11	5,8	14	0	CVPG	1,98	0,017	16%	1,66	2,3	14		
(4) LIA (CLIA, CMIA, ECLIA); (179)	Siemens (Bayer)	1,44	0,36	25	6	0	CVPG	1,47	0,067	16%	1,23	1,71	6		
Other					6	0							5		
		1x 1/36, 4x 4/29, 1x 4/149													

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

Test	[unit]						Comparability						N _{eva}	N _{suc}	S _{rel}
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL				
Sample B		36,2	5,4	15	55								54	52	96%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		39,2	2,7	6,9	17	0	CVPG	39,9	0,59	16%	33,5	46,3	17		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		36,4	2,9	7,9	12	0	CVPG	38	0,89	16%	31,9	44,1	12		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		30,2	1,3	4,3	14	0	CVPG	29,1	0,33	16%	24,4	33,8	14		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		37,3	3,4	9,2	6	0	CVPG	36,2	0,71	16%	30,4	42	6		
Other					6	0							5		
								1x 1/36, 4x 4/29, 1x 4/149							
(191) PSA					66								65	61	94%
Samples and groups	[µg/L]														
Sample A		8,22	1,3	16	66								65	62	95%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		6,83	0,37	5,4	19	0	CVPG	6,76	0,085	15%	5,74	7,78	19		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		9,99	1,2	12	11	0	CVPG	10,1	0,16	15%	8,58	11,7	11		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		8,68	0,48	5,6	5	0	CVPG	9,03	0,20	15%	7,67	10,4	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		8,95	0,36	4,1	21	0	CVPG	8,87	0,053	15%	7,53	10,2	21		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		7,75	0,39	5,0	5	0	CVPG	7,75	0,094	15%	6,58	8,92	5		
Other					5	0							4		
								1x 1/36, 2x 4/149, 2x 4/195							
Sample B		8,61	1,6	19	66								65	63	97%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		6,88	0,39	5,7	19	0	CVPG	6,83	0,12	15%	5,8	7,86	19		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		10,6	0,68	6,4	11	0	CVPG	10,5	0,19	15%	8,92	12,1	11		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		9,79	0,31	3,2	5	0	CVPG	9,65	0,28	15%	8,2	11,1	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		9,27	0,62	6,7	21	0	CVPG	8,97	0,098	15%	7,62	10,4	21		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		8,27	0,33	4,0	5	0	CVPG	8,05	0,14	15%	6,84	9,26	5		
Other					5	0							4		
								1x 1/36, 2x 4/149, 2x 4/195							
(194) NSE					24								24	24	100%
Samples and groups	[µg/L]														
Sample A		43,3	2,8	6,4	24								24	24	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		43,7	2,4	5,5	17	0	CVPG	43,2	0,49	30%	30,2	56,2	17		
Other					7	0							7		
								3x 4/164, 2x 4/256, 2x 4/259							
Sample B		14,3	2,3	16	24								24	24	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		14,9	1,3	8,9	17	0	CVPG	14,5	0,25	30%	10,1	18,9	17		
Other					7	0							7		
								3x 4/164, 2x 4/256, 2x 4/259							
(195) SCCA					20								18	16	89%
Samples and groups	[µg/L]														
Sample A		8,90	2,1	23	20								18	17	94%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		9,80	0,57	5,8	13	0	CVPG	10,2	0,20	23%	7,85	12,6	13		
Other					7	0							5		
								2x 3/24, 1x 3/25, 1x 3/98, 3x 4/60							
Sample B		2,12	0,52	25	20								18	16	89%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		2,20	0,22	10	13	0	CVPG	2,18	0,095	±0,7	1,48	2,88	13		
Other					7	0							5		
								2x 3/24, 1x 3/25, 1x 3/98, 3x 4/60							
(196) TPA					5								4	4	100%
Samples and groups	[U/L]														
Sample A		1290	120	9,4	5								4	4	100%
Other					5	0							4		
								1x 2/66, 4x 4/164							
Sample B		783	140	18	5								4	4	100%
Other					5	0							4		
								1x 2/66, 4x 4/164							
(198) free-PSA					65								64	62	97%
Samples and groups	[µg/L]														
Sample A		6,34	0,76	12	65								64	62	97%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		6,74	0,35	5,1	19	0	CVPG	6,6	0,081	16%	5,54	7,66	19		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		7,68	0,71	9,2	10	0	CVPG	7,67	0,20	16%	6,44	8,9	10		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		5,81	0,73	13	5	0	CVPG	5,96	0,20	16%	5	6,92	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		5,79	0,32	5,5	21	0	CVPG	5,81	0,042	16%	4,88	6,74	21		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of groups n = 5

EQA round: TM1/19 - Tumour Markers

Dead line: 12.02.2019

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(198) free-PSA					65								64	62	97%
Samples and groups	[µg/L]														
Sample A		6,34	0,76	12	65								64	62	97%
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		6,01	0,21	3,5	5	0	CVPG	5,94	0,092	16%	4,98	6,9	5		
Other					5	0							4		
								1x 1/36, 2x 4/149, 2x 4/195							
Sample B		6,90	0,85	12	65								64	64	100%
(4) LIA (CLIA, CMIA, ECLIA); (1) Abbott		7,17	0,53	7,4	19	0	CVPG	7,05	0,097	16%	5,92	8,18	19		
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		8,52	0,51	6,0	10	0	CVPG	8,23	0,21	16%	6,91	9,55	10		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		6,32	0,37	5,9	5	0	CVPG	6,27	0,24	16%	5,26	7,28	5		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		6,37	0,42	6,7	21	0	CVPG	6,3	0,059	16%	5,29	7,31	21		
(4) LIA (CLIA, CMIA, ECLIA); (179) Siemens (Bayer)		6,70	0,16	2,4	5	0	CVPG	6,43	0,13	16%	5,4	7,46	5		
Other					5	0							4		
								1x 1/36, 2x 4/149, 2x 4/195							
(201) S-100					17								17	17	100%
Samples and groups	[µg/L]														
Sample A		0,100	0,004	4,6	17								17	17	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		0,100	0,003	3,6	12	0	CVPG	0,099	,0017	32%	0,067	0,131	12		
Other					5	0							5		
								1x 4/164, 4x 4/256							
Sample B		0,075	0,009	12	17								17	17	100%
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		0,078	0,004	5,3	12	0	CVPG	0,078	,0012	32%	0,053	0,103	12		
Other					5	0							5		
								1x 4/164, 4x 4/256							
(206) Calcitonin					12								10	8	80%
Samples and groups	[ng/L]														
Sample A		4,98	0,88	18	12								10	9	90%
Other					12	0							10		
								2x 1/134, 3x 4/29, 3x 4/60, 4x 4/164							
Sample B		8,68	1,7	19	12								10	9	90%
Other					12	0							10		
								2x 1/134, 3x 4/29, 3x 4/60, 4x 4/164							
(207) Thyreoglobulin					30								28	26	93%
Samples and groups	[µg/L]														
Sample A		150	20	13	30								28	26	93%
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		154	11	7,2	7	0	CVPG	153	4,6	30%	107	199	7		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		125	17	14	7	0	CVPG	128	5,6	30%	89,6	167	7		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		161	4,1	2,6	13	0	CVPG	158	2,3	30%	110	206	13		
Other					3	0							1		
								1x 1/36, 1x 3/25, 1x 4/164							
Sample B		21,9	8,7	40	30								28	26	93%
(4) LIA (CLIA, CMIA, ECLIA); (12) Beckman Coulter		19,8	2,9	15	7	0	CVPG	20,1	2,1	30%	14	26,2	7		
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		12,5	2,1	17	7	0	CVPG	12,4	0,75	30%	8,68	16,2	7		
(4) LIA (CLIA, CMIA, ECLIA); (60) Roche		28,9	3,5	12	13	0	CVPG	27,7	0,92	30%	19,3	36,1	13		
Other					3	0							1		
								1x 1/36, 1x 3/25, 1x 4/164							
(208) beta-2-microglobulin					28								26	25	96%
Samples and groups	[mg/L]														
Sample A		1,54	0,19	13	28								26	25	96%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		1,70	0,15	8,7	6	0	CVPG	1,69	0,077	21%	1,33	2,05	6		
(6) IMT, IMN; (60) Roche		1,58	0,033	2,1	8	0	CVPG	1,57	0,018	21%	1,24	1,9	8		
Other					14	0							12		
								1x 2/147, 1x 4/60, 1x 4/149, 2x 4/164, 1x 6/1, 3x 6/12, 1x 6/58, 2x 6/91, 1x 6/149, 1x 6/179							
Sample B		1,49	0,19	13	28								26	26	100%
(4) LIA (CLIA, CMIA, ECLIA); (29) Siemens (DPC)		1,51	0,21	14	6	0	CVPG	1,6	0,10	21%	1,26	1,94	6		
(6) IMT, IMN; (60) Roche		1,54	0,16	10	8	0	CVPG	1,53	0,039	21%	1,2	1,86	8		
Other					14	0							12		
								1x 2/147, 1x 4/60, 1x 4/149, 2x 4/164, 1x 6/1, 3x 6/12, 1x 6/58, 2x 6/91, 1x 6/149, 1x 6/179							

st_kn_p

End of report

Printed: 27.02.2019